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Introduction: Neurocysticercosis (NCC) is one of the 
leading causes of epilepsy worldwide. The majority of 
cases in Europe are diagnosed in immigrants. Currently 
in Italy, routine serological screening for cysticercosis 
is recommended for internationally adopted children 
(IAC) coming from endemic countries.  Methods:  We 
retrospectively analyse the results of the serologi-
cal screening for cysticercosis in IAC 16 years old or 
younger, attending two Italian third level paediatric 
clinics in 2001–16. Results: Of 2,973 children included 
in the study, 2,437 (82.0%) were screened by enzyme-
linked immune electro transfer blot (EITB), 1,534 
(51.6%) by ELISA, and 998 (33.6%) by both tests. The 
seroprevalence of cysticercosis ranged between 1.7% 
and 8.9% according to EITB and ELISA, respectively. 
Overall, 13 children were diagnosed with NCC account-
ing for a NCC frequency of 0.4% (95% confidence 
interval (CI): 0.2–0.6%). Among the 168 seropositive 
children, only seven (4.2%) were diagnosed with NCC. 
Of these children, three were asymptomatic and four 
presented epilepsy. Among seronegative children 
(n = 2,805), seven presented with neurological symp-
toms that lead to the diagnosis of NCC in six cases. The 
sensitivity, specificity, positive and negative predic-
tive value for the diagnosis of NCC were 54.5%, 98.6%, 
14.6%, 99.8% for EITB and 22.2%, 91.1%, 1.4%, 99.5% 
for ELISA. The yield of the screening programme was 
437 NCC cases per 100,000. The number needed to 
screen to detect one NCC case was 228. The cost per 
NCC case detected was EUR 10,372. Conclusion: On the 
base of our findings we suggest the ongoing serologi-
cal screening for cysticercosis to be discontinued, at 
least in Italy, until further evidence in support will be 
available
Introduction
Human cysticercosis is due to the invasion of tissues 
by the metacestode larval stage of  Taenia solium  [1]. 
The central nervous system is the most clinically rel-
evant localisation of the parasite, which in this case 
causes neurocysticercosis (NCC) [1]. T. solium and NCC 
are currently endemic in large areas of Latin America, 
sub-Saharan Africa, and Asia, including the Indian 
subcontinent, most of south-east Asia, and China [1]. 
In the United States (US) and Western Europe, the 
disease is mainly imported [2,3]. The World Health 
Organization in 2017 reported that the total estimated 
number of people with NCC in endemic areas range 
between 2.56 million and 8.30 million [4]. In Western 
Europe, according to the latest systematic review avail-
able, only 275 cases of cysticercosis were reported 
in the period 1990–2015, of whom only 5% were sus-
pected to be autochthonous [5].
NCC is the most frequent preventable cause of epilepsy 
in the developing world [6] being responsible for ca 
30% of cases of epilepsy in low income countries [7,8]. 
More severe manifestations such as focal neurologic 
deficits, intracranial hypertension, cognitive decline 
and chronic meningitis are more rarely observed [1]. 
Children are less frequently affected by NCC than 
adults [9-11], probably due to mechanisms involved in 
disease acquisition and differences in the reactivity 
of the immune system against the parasite. However, 
NCC is responsible for a non-negligible portion of 
2 www.eurosurveillance.org
epilepsy cases in children as well. In Northern India, 
the reported NCC prevalence was 4.5% among children 
aged 1 to 14 years presenting to a tertiary care hospital 
with a first episode of seizure or acute focal neurologi-
cal deficit [12]. According to another community-based 
study conducted in the city of Kolkata, India, the preva-
lence of NCC among patients aged 19 years or less with 
active epilepsy was 23.4% [13]. In Lima, Peru, NCC was 
found to be the main cause of partial seizure among 
preschool and school-aged children accessing a public 
hospital, accounting for 37% of cases [14]. According 
to large case series observed in Europe and in the US, 
paediatric patients account for 21–26% of NCC cases, 
the majority of them diagnosed in immigrant children 
or children who had travelled to endemic areas [15,16]. 
Internationally adopted children (IAC) represent a con-
siderable and peculiar portion of immigrant children. 
Thousands of children are internationally adopted 
each year from lower income countries, especially 
in European countries, in the US and Canada [17]. 
Although children are declared healthy in their home 
countries, medical disorders are often missed, with 
diagnosis only occuring after adoption [18-21]. For 
these reasons, IAC usually undergo a comprehensive 
medical evaluation upon arrival in the host country, 
where frequently unsuspected disorders such as infec-
tions are identified [20,22].
In the period 2001–15, ca 3,000 IAC arrived in Italy 
each year (range ca 1,800–4,000). Of them, about 50% 
came from other European countries, ca 25% from the 
Americas, ca 15% from Asia and ca 10% from Africa 
(Supplement: Table 1). Upon arrival to Italy (usually 
within 3–4 months), IAC usually undergo a comprehen-
sive medical evaluation according to a protocol sug-
gested by the ‘National Working Group for the Migrant 
Child’ of the Italian Society of Paediatrics in one of the 
19 dedicated reference centres, identified by the Italian 
Society of Paediatrics [23]. The medical screening pro-
tocol suggests to investigate the presence of several 
non-infectious and infectious diseases, including NCC. 
According to the latest version of the Italian Society 
of Paediatrics protocol issued in 2013, the medical 
evaluation of IAC includes a serological screening test 
for cysticercosis (the method of serological testing is 
not specified) for children coming from Asia and Latin 
America (including the Caribbean), while in previous 
versions that covered the study period, the serologi-
cal screening was recommended for Asian and Latin 
American children, as well as for African ones [24-
26]. Individuals with a positive test for cysticercosis 
undergo a full clinical assessment including, at least 
in the two paediatric reference centres participat-
ing in the current study, a brain Magnetic Resonance 
Imaging (MRI). Whereas the serology-based screening 
for NCC in IAC is widely used in Italy, and even in other 
countries such as France [27], there are few data on 
the yield, cost and performance of this strategy. The 
objective of this study was to evaluate the yield, cost 
and performance of a serological screening protocol for 
NCC in IAC.
Methods
Study design and population
This was an observational retrospective study. We 
included all IAC aged 16 years or less, who consecu-
tively underwent a serological test for cysticercosis in 
a 16 year period (from 1 January 2001 to 31 December 
2016) at two paediatric reference centres for IAC, 
namely the Infectious Diseases Unit, Meyer University 
Hospital, Department of Health Science, University 
of Florence, Florence, Italy (MY) and the Department 
of Paediatrics, Sacro Cuore – Don Calabria Hospital, 
Negrar, Italy (NE). During the study period, except for 
after 2013, when children from Africa were no longer 
recommended for screening, the protocol of the 
‘National Working Group for the Migrant Child’ of the 
Italian Society of Paediatrics suggested that the test 
for cysticercosis should be offered to all IAC coming 
from Latin American, African, Asian countries. Of note, 
some IAC coming from Eastern European countries 
were sometimes screened for cysticercosis despite not 
Table 1
Different serological tests for cysticercosis used in two paediatric reference centres for internationally adopted children ≤16 
years old, Italy, 2001–2016
Period Meyer University Hospitala Sacro Cuore-Don Calabria Hospitalb
2001–2004 EITBc ELISAd
2005–2006 EITBc ELISAd + EITBe
2007–2015 EITBc ELISAd + EITBc
2016 EITBc EITBc
EITB: enzyme-linked immune electro transfer blot; ELISA: enzyme-linked immunosorbent assay; US: United States.
a Infectious Diseases Unit, Meyer University Hospital, Florence, Italy.
b Department of Paediatrics, Sacro Cuore-Don Calabria Hospital, Negrar, Italy.
c Cysticercosis Western blot IgG, LDBIO Diagnostics, Lyon, France.
d Taenia Solium IgG, DRG International Inc, Springfield, US.
e QualiCode Cysticercosis kit, Immunetics Inc., Boston, Massachusetts, US.
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being mentioned in the protocol. Likewise, after 2013, 
some children from Africa were occasionally tested.
Data source and data extraction
Epidemiological and clinical data (including some 
laboratory results of routine tests performed when 
the individuals accessed the centres) were extracted 
by consulting the clinical records. For every child, the 
following data were retrieved and collected using an 
electronic Excel database: age, sex, geographical area 
of the world and country of birth, date of visit, type of 
cysticercosis serological test performed and its result, 
absolute eosinophil count, result of stool parasitologi-
cal test, presence or absence of neurological symp-
toms, diagnosis of NCC according to the diagnostic 
criteria proposed by Del Brutto et al. (in 2017) [28].
For individuals diagnosed with NCC according to the 
aforementioned criteria, detailed epidemiological, 
clinical, laboratory and radiology information to ascer-
tain the presence or absence of each diagnostic criteria 
were checked and registered in an additional database. 
Supplement Table 2 reports Del Brutto et al. diagnostic 
criteria (2017 version) and their interpretation.
Serological test for cysticercosis
At the MY, individuals were screened with a commer-
cial enzyme-linked immune electro transfer blot (EITB) 
test on serum (Cysticercosis western blot IgG) pro-
duced by LDBIO Diagnostics (Lyon, France) throughout 
the study period (2001–16). The test was performed 
and interpreted according to the test manufacturer’s 
instructions that varied over the years. In the period 
2001–13, the presence of at least one of five specific 
bands (6–8kDa, 12kDa, 23–26kDa, 39kDa, 50–55kDa) 
was considered as a criterion of positivity. From 2014 
onwards, the presence of at least two specific bands 
was required for considering a test positive [29].
At the NE centre, in the period 2001–4, serum samples 
were tested with an enzyme-linked immunosorbent 
assay (ELISA) test. In the period 2005–15 serum sam-
ples were tested in parallel with ELISA and EITB, while 
since 2016 only EITB was used. The ELISA test used 
was a commercial one (ELISA, Taenia Solium IgG, DRG 
International Inc, Springfield, US). The test was per-
formed and interpreted according to the manufacturer’s 
instruction. Absorbance equal to or greater than 0.3 
(dilution 1:64 on 100 µL of serum) was considered as 
corresponding to a positive test result [30]. In the period 
2005–6 the EITB used was Qualicode Cysticercosis kit 
(Immunetics Inc., Boston, Massachusetts, US), and the 
test was considered positive in presence of at least 
one of the specific bands (50 KDa, 42–39kDa, 24kDa, 
21kDa, 18kDa, 14kDa, 13kDa) [31]. From 2007, the EITB 
produced by Immunetics was replaced by the EITB 
Figure 
Flow chart of the screening process for cysticercosis in internationally adopted children, Italy, 2001–2016 (n = 2,973 children 
≤16 years old screened)
2,973 
internationally adopted children
Serological test for cysticercosis
168 seropositive 
(5.7%)
2,805 seronegative 
(94.3%)
7 seronegative children
with compatible NCC symptoms
2,798 seronegative children
asymptomatic
Full clinical assessment including a brain MRI
1 diagnosis of NCC excluded
6 diagnosis of NCC
Full clinical assessment including a brain MRI
7 diagnosis of NCC
161 diagnosis of NCC excluded
3 asymptomatic 4 compatible NCC symptoms
MRI: magnetic resonance imaging; NCC: neurocysticercosis.
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produced by LDBIO Diagnostics, interpreted according 
to the manufacturer’s instruction (as for the MY cen-
tre). In 2016, persons evaluated in NE were tested only 
with the EITB. Table 1 summarises the serological tests 
for cysticercosis used during the study period in the 
two centres.
Data analysis
For the analysis purpose, EITB tests performed with 
the different kits (Immunetics and LDBIO) were consid-
ered as one test. The following parameters were esti-
mated: seroprevalence for cysticercosis according to 
the different serological tests used (ELISA and EITB), 
sex, age, country and world geographical area of birth; 
frequency of NCC (diagnosed according to the diagnos-
tic criteria proposed by Del Brutto et al. in 2017, see 
Supplement: Table 2) according to sex, age, country 
and geographical area of birth; sensitivity, specificity, 
positive predictive value (PPV) and negative predic-
tive value (NPV) of EITB and ELISA considering as gold 
standard the diagnosis of NCC according to the diag-
nostic criteria proposed by Del Brutto et al. in 2017; 
association (with chi-squared test) between positivity 
to ELISA or EITB and eosinophilia (> 450 eosinophils 
per µL) and diagnosis of other helminthic infections; 
association (with chi-squared test) between diagnosis 
of NCC according to the diagnostic criteria proposed by 
Del Brutto et al. in 2017 and eosinophil count.
All of the data were analysed using IBM SPSS 19.0 soft-
ware (IBM, Armonk, NY, US).
Performance and costs of the screening 
protocol
The following performance and economic indicators 
were calculated: yield of the screening, number needed 
to screen to detect one case (NNS), and cost per case 
detected.
The definitions used for the performance and economic 
indicators were the following:
(i) Yield = number of NCC cases identified / total num-
ber of individuals screened × 100,000.
(ii) Number needed to screen to detect one case = total 
number screened / number of cases identified.
(iii) The costs of the screening algorithm were applied 
to the number of NCC cases diagnosed to give indicative 
costs per case of NCC detected: this was done by divid-
ing the relative total cost of the tests in the algorithm 
by the number of NCC cases identified. To estimate the 
costs of the screening algorithm, we considered the 
costs of the services included: one (or two) serologi-
cal tests for cysticercosis for all children and a brain 
MRI without contrast together with a clinical evaluation 
for all seropositive children as well as for seronegative 
children with compatible NCC signs/symptoms. Except 
for ELISAs (see below), the costs of these services were 
extracted from the ‘Catalogo Aziendale 2016’ of the 
Azienda Ospedaliero-Universitaria Careggi, Florence, 
Italy, which is a database reporting the list of stand-
ard set of medical services available in the Azienda 
Ospedaliero-Universitaria Careggi and their costs [32]. 
The costs of the considered services are similar in other 
Italian Regions. The cost of the cysticercosis ELISA 
serological test was extrapolated from the ‘Catalogo 
Regionale 2016’ of the Veneto Region [33].
This report was written according to the STrengthening 
the Reporting of OBservational studies in Epidemiology 
(STROBE) Statement guidelines.
Results
The Figure  reports the flow chart of screening. A total 
of 2,973 children who underwent a serological test 
for cysticercosis were included, 1,684 (56.6%) boys 
and 1,269 (42.7%) girls, while for 20 (0.7%) the sex 
was not available. These children accounted for ca 
13% of the IAC from NCC endemic countries arriving 
in Italy in the study period (Supplement: Table 1). The 
median age was 6 years (interquartile range (IQR): 
3–8). According to the origin in terms of geographical 
area, 1,271 (42.7%) were from Asia, 1,073 (36.1%) from 
Latin America/Caribbean, 516 (17.4%) from Africa, 27 
(0.9%) from Europe, and for 86 (2.9%) the country of 
origin was unknown. An EITB was used to screen 2,437 
(82.0%) of the children, including 2,389 with the test 
Table 2
Estimations of seroprevalence for cysticercosis in internationally adopted children ≤16 years old according to the test used 
and the clinical centre, Italy, 2001–2016 (n = 2,973 children testeda)
Test
Meyer University Hospitalb Sacro Cuore Don Calabria Hospitalc All
n/N % n/N % n/N %
EITB 10/1,315 0.8 31/1,122 2.8 41/2,437 1.7
ELISA 0/0 NA 137/1,534 8.9 137/1,534 8.9
EITB: enzyme-linked immune electro transfer blot; ELISA: enzyme-linked immunosorbent assay; n: number of individuals testing positive in 
serology for cysticercosis; N: total number of tested patients; NA: not applicable.
a Some children were tested with only EITB, others with only ELISA, and some with both.
b Infectious Diseases Unit, Meyer University Hospital, Florence, Italy.
c Department of Paediatrics, Sacro Cuore Hospital-Don Calabria, Negrar, Italy.
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produced by LDBIO and 48 with the test produced by 
Immunetics. The ELISA test was employed to screen 
1,534 (51.6%) adoptees. There were 998 (33.6%) indi-
viduals screened with both ELISA and EITB tests. 
Seroprevalence for cysticercosis
There were 168 (5.7%; 95% confidence interval (CI): 
5.0–6.6) children seropositive to at least one test, 127 
to ELISA only, 31 to an EITB only and 10 to both ELISA 
and EITB. The seroprevalence of cysticercosis with 
EITB (either LDBIO or Immunetics) interpreted accord-
ing to the manufacturer was 1.7% (41/2,437; 95% CI: 
1.2–2.2) while with ELISA it was 8.9% (137/1,534; 95% 
CI: 7.5–10.3).  Table 2  reports in detail the seropreva-
lence according to the test used and the clinical centre. 
The seroprevalence in boys or girls was not signifi-
cantly different, regardless of the laboratory test used 
to estimate it, i.e. EITB (either LDBIO or Immunetics, 
Table 3a
Seroprevalence for cysticercosis and frequency of neurocysticercosis in internationally adopted children ≤16 years old 
according to the country and geographical area of birth, Italy, 2001–2016 (n = 2,973 children)
Geographical area and country of birth
EITB ELISA Frequency of NCC
na/N % na/N % nb/N %
AFRICA 9/463 1.9 9/151 6.0 4/522 0.8
Benin 0/1 0.0 0/0 0.0 0/1 0.0
Burkina Faso 1/39 2.6 0/3 0.0 1/39 2.6
Cameroon 0/1 0.0 0/1 0.0 0/1 0.0
Cape Verde 0/1 0.0 0/0 0.0 0/1 0.0
Côte d’Ivoire 0/3 0.0 0/0 0.0 0/3 0.0
Eritrea 0/4 0.0 0/0 0.0 0/4 0.0
Ethiopia 6/301 2.0 9/128 7.0 0/353 0.0
The Gambia 0/1 0.0 0/0 0.0 0/1 0.0
Ghana 0/0 0.0 0/3 0.0 0/3 0.0
Guinea-Bissau 0/3 0.0 0/1 0.0 1/3 33.3
Kenya 0/17 0.0 0/2 0.0 0/17 0.0
Madagascar 0/4 0.0 0/2 0.0 0/6 0.0
Mali 0/8 0.0 0/0 0.0 0/8 0.0
Morocco 0/5 0.0 0/2 0.0 0/6 0.0
Nigeria 0/2 0.0 0/0 0.0 0/2 0.0
Democratic Republic of the Congo 1/63 1.6 0/8 0.0 2/63 3.2
Senegal 0/2 0.0 0/0 0.0 0/2 0.0
Somalia 0/2 0.0 0/0 0.0 0/2 0.0
Uganda 0/0 0.0 0/1 0.0 0/1 0.0
Unspecified country 1/6 16.6 0/0 0.0 0/6 0.0
ASIA 22/889 2.5 93/854 10.9 6/1,271 0.5
Armenia 0/2 0.0 0/0 0.0 0/2 0.0
Bangladesh 0/3 0.0 0/3 0.0 0/4 0.0
Cambodia 0/89 0.0 4/59 6.8 0/97 0.0
China 0/37 0.0 0/26 0.0 0/37 0.0
Philippines 0/34 0.0 0/6 0.0 0/34 0.0
India 20/530 3.8 83/633 13.1 4/870 0.5
Kazakhstan 0/3 0.0 0/0 0.0 0/3 0.0
Nepal 2/74 2.7 2/68 2.9 1/94 1.1
Pakistan 0/4 0.0 1/4 25.0 0/4 0.0
Sri Lanka 0/17 0.0 0/5 0.0 0/17 0.0
Thailand 0/7 0.0 0/2 0.0 0/7 0.0
Vietnam 0/87 0.0 2/37 5.4 1/91 1.1
Unspecified country 0/2 0.0 1/11 9.10 0/11 0.0
EITB: enzyme-linked Immune electro transfer blot; ELISA: enzyme-linked immunosorbent assay; N: total number of patients tested with a 
serological test for cysticercosis; NCC: neurocysticercosis.
a Number of individuals testing positive in a serological test for cysticercosis.
b Number of children diagnosed with neurocysticercosis according to the criteria proposed by Del Brutto et al. in 2017 (probable or definitive 
diagnosis).
c European part of Russia.
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interpreted according to the manufacturer), or ELISA. 
Indeed, the seroprevalence obtained with EITB was 
1.8% (26/1,417; 95% CI: 1.1–2.5) for boys and 1.5% 
(15/1,000; 95% CI: 0.8–2.2) for girls (p value = 0.6429). 
With ELISA this was 8.8% (75/856; 95% CI: 6.9–10.7) 
for boys and 9.1% (62/678; 95% CI: 6.9–11.3) for girls 
(p value = 0.8642).
The seroprevalence of cysticercosis according to 
the country and continent of origin of the children is 
reported in Table 3.
Frequency of neurocysticercosis according to 
the 2017 version of Del Brutto et al. criteria
NCC was diagnosed according to the 2017 version of 
Del Brutto et al. criteria in 13 children accounting for 
a frequency of 0.4% (13/2,973; 95% CI: 0.2–0.6) in 
the study population. According to these criteria, 10 
were diagnosed as definitive cases and three as prob-
able cases (Supplement: Table 3). Among 13 children 
with a diagnosis of NCC (2017 version of Del Brutto 
et al. criteria), seven were seropositive to at least a 
serological test for cysticercosis (five were positive to 
EITB only, one to both EITB and ELISA, one to ELISA 
only). NCC was diagnosed in 4.2% of all seropositive 
children (7/168). Among children with a diagnosis 
of NCC, six of 13 were seronegative for cysticercosis. 
These children presented with neurological symptoms 
(epilepsy) that lead to the diagnosis of NCC follow-
ing a full clinical assessment, which included at least 
a brain MRI. Of seropositive children with NCC, three 
Geographical area and country of birth
EITB ELISA Frequency of NCC
na/N % na/N % nb/N %
LATIN AMERICA/CARIBBEAN 10/1,016 1.0 32/465 6.9 3/1,073 0.3
Argentina 0/1 0.0 0/0 0.0 0/1 0.0
Bolivia 1/81 1.2 3/53 5.7 0/91 0.0
Brazil 4/248 1.6 9/112 8.0 1/269 0.4
Chile 1/86 1.2 1/17 5.9 0/87 0.0
Colombia 2/383 0.5 13/188 6.9 2/397 0.5
Costa Rica 1/26 3.8 0/2 0.0 0/26 0.0
Ecuador 0/14 0.0 0/16 0.0 0/17 0.0
El Salvador 0/1 0.0 0/0 0.0 0/1 0.0
Guatemala 0/4 0.0 0/1 0.0 0/4 0.0
Haiti 0/12 0.0 0/4 0.0 0/12 0.0
Honduras 0/4 0.0 0/1 0.0 0/4 0.0
Mexico 0/4 0.0 0/3 0.0 0/6 0.0
Nicaragua 0/1 0.0 0/0 0.0 0/1 0.0
Peru 1/147 0.7 6/65 9.2 0/152 0.0
Dominican Republic 0/4 0.0 0/2 0.0 0/4 0.0
Unspecified country 0/0 0.0 0/1 0.0 0/1 0.0
EUROPE 0/22 0.0 1/7 14.3 0/27 0.0
Albania 0/1 0.0 0/1 0.0 0/2 0.0
Bosnia and Herzegovina 0/0 0.0 0/1 0.0 0/1 0.0
Bulgaria 0/4 0.0 0/0 0.0 0/4 0.0
Latvia 0/1 0.0 0/0 0.0 0/1 0.0
Lithuania 0/3 0.0 0/0 0.0 0/3 0.0
Moldova 0/2 0.0 0/0 0.0 0/2 0.0
Poland 0/2 0.0 0/0 0.0 0/2 0.0
Russiac 0/7 0.0 0/2 0.0 0/7 0.0
Serbia 0/1 0.0 0/0 0.0 0/1 0.0
Ukraine 0/1 0.0 1/3 33.3 0/4 0.0
Unspecified origin 0/47 0.0 2/57 3.5 0/80 0.0
EITB: enzyme-linked Immune electro transfer blot; ELISA: enzyme-linked immunosorbent assay; N: total number of patients tested with a 
serological test for cysticercosis; NCC: neurocysticercosis.
a Number of individuals testing positive in a serological test for cysticercosis.
b Number of children diagnosed with neurocysticercosis according to the criteria proposed by Del Brutto et al. in 2017 (probable or definitive 
diagnosis).
c European part of Russia.
Table 3b
Seroprevalence for cysticercosis and frequency of neurocysticercosis in internationally adopted children ≤16 years old 
according to the country and geographical area of birth, Italy, 2001–2016 (n = 2,973 children)
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were asymptomatic and four symptomatic (epilepsy). 
Nine of the 10 symptomatic children with NCC (four 
seropositive and six seronegative) had active or degen-
erating NCC lesions at neuroimaging, while one child 
had only calcified lesions. Among the three asympto-
matic seropositive individuals, all three had active or 
degenerating lesions. According to the type of brain 
lesions, seven children had a single brain lesion each 
(all enhancing lesions; three seropositive, four seron-
egative), one had two lesions (cysts without scolex; 
seropositive), four had three or more enhancing lesions 
(three seropositive, one seronegative), one had calci-
fication only (seronegative). Children with active or 
degenerating lesions were treated with albendazole 
and corticosteroids. Individuals with epilepsy were 
treated with antiepileptic drugs.
The frequency of NCC in boys and girls was not sig-
nificantly different (0.5% (8/1,684; 95% CI: 0.2–0.8) 
and 0.4% (5/1,269; 95% CI: 0.1–0.7), respectively, p 
value = 0.7419). The median age of children with and 
without NCC was not significantly different: 6 and 6 
years respectively (p value = 0.6324). The prevalence of 
eosinophilia (defined as eosinophil count > 450 per µL) 
among individuals with available data was not statisti-
cally different among patients with NCC (4/13, 30.8%; 
95% CI: 5.7–55.9) and those without NCC (446/933, 
47.8%; 95% CI: 44.6–51) (p value = 0.3464).
The frequencies of NCC according to the country and 
geographical area of origin of the children are reported 
in Table 3.
Sensitivity, specificity, PPV and NPV of EITB and 
ELISA considering as gold standard the diagnosis of 
NCC (probable and definitive diagnosis, according to 
the 2017 diagnostic criteria by Del Brutto et al.) are 
reported in Table 4.
The associations between EITB and ELISA positivity 
and eosinophilia and the diagnosis of other helminthic 
infection are reported in  Table 5. Noteworthy, there 
was a statistically significant correlation between 
infection due to  Hymenolepis nana  and positivity of 
either EITBs or ELISA. Of the 1,638 children undergoing 
parasitological stool examination, the following 
helminthic infections were diagnosed: H. nana (n = 285; 
17.4%)  Trichuris trichiura  (n = 44), hookworms 
(n = 17),  Schistosoma  spp. (n = 12),  Strongyloides ster-
coralis  (n = 8),  Enterobius vermicularis  (n = 4),  Taenia 
saginata (n = 3) and T. solium (n = 1).
Performance and costs of the screening protocol: the 
yield of the screening programme was 437/100,000, 
in our population. The NNS was 228. The cost of the 
screening was EUR 134,831 and EUR 8,426.9 for the 16 
years period and per year in mean respectively and the 
cost per case detected was EUR 10,372 (Table 6). 
Discussion
The present study reveals a substantial seroprevalence 
of cysticercosis in IAC ranging between 1.7% and 8.9% 
depending on the test used (EITB and ELISA, respec-
tively), while the frequency of NCC was 0.4%. According 
to the geographical area of origin, the frequency of 
NCC was higher in IAC from Africa (0.8%) compared 
with Asia (0.5%), Latin America/Caribbean (0.3%) 
and Europe (0%). This finding confirms that, even if 
cysticerocosis/T. solium taeniasis has been considered 
for a long time endemic mainly in Latin America and 
South-East Asia, the disease is present also in large 
areas of Sub-Saharan Africa, as suggested by accu-
mulating evidence [4,34]. Of note, this result does not 
support the most recent version of the Italian protocol 
of the ‘National Working Group for the Migrant Child’ 
of the Italian Society of Paediatrics [25] to exclude IAC 
from Africa among children screened from NCC.
There are few smaller previous studies investigating 
the performance of a serological screening for cyst-
icercosis and NCC in IAC. In a French study, carried out 
by Blanchi et al., only IAC from Haiti and Madagascar 
(considered at high risk) were serologically screened 
for cysticercosis. In this study, only one of 25 Haitian 
children was seropositive (the authors did not specify 
whether the patient was affected by NCC or cysticer-
cosis) [27]. According to a study conducted in Italy by 
Valentini et al., children from Asia, Africa and Latin 
America were serologically screened for cysticercosis 
with an ELISA test, and those testing positive were 
tested with an EITB for confirmation. Thirty-two of 358 
(8.9%) children were seropositive by ELISA, but none 
by EITB [22]. The authors of these two previous studies 
reached opposite conclusions. Blanchi et al. suggested 
Table 4
Sensitivity, specificity, positive predictive value and 
negative predictive value of EITB and ELISA cysticercosis 
tests, for the diagnosis of neurocysticercosisa in 
internationally adopted children ≤16 years old, Italy, 
2001–2016
Test
Sensitivity Specificity
PPV (%) NPV (%)nb/Nc % nd/Ne %
EITB 6/11a 54.5 2,391/2,426 98.6 14.6 99.8
ELISA 2/9a 22.2 1,390/1,525 91.1 1.4 99.5
EITB: enzyme-linked immune electro transfer blot; ELISA: enzyme-
linked immunosorbent assay; NCC: neurocysticercosis; 
NPV: negative predictive value; PPV: positive predictive value.
a Among the 13 patients with a diagnosis of NCC, all were tested 
with at least one serological test: seven with both ELISA and 
EITB, two with ELISA only and four with EITB only. In total, 11 
were tested with EITB and nine with ELISA. The diagnosis of NCC 
was according to the diagnostic criteria proposed by Del Brutto 
et al. in 2017 (probable and definitive diagnosis).
b Number of NCC-diagnosed children who were respectively found 
seropositive for cysticercosis by EITB or ELISA.
c Number of NCC-diagnosed children who were respectively 
serologically tested for cysticercosis by EITB or ELISA.
d Number of children who tested seronegative for cysticercosis 
either by EITB or ELISA, excluding those with a diagnosis of NCC.
e Number of children who were serologically tested for 
cysticercosis by either EITB or ELISA, excluding those with a 
diagnosis of NCC.
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that serological screening of asymptomatic IAC from 
highly endemic countries for cysticercosis should be 
mandatory, since it can help to detect asymptomatic 
patients with lesions allowing their treatment before 
the symptoms appear. On the contrary, Valentini et 
al. suggested that the screening in asymptomatic IAC 
could be avoided given the absence of EITB confirmed 
positive results.
In the majority of cases, patients with NCC develop 
symptoms some years after the infection occurred. For 
example, according to a systematic review of the litera-
ture, 73.6% of patients with imported NCC in Europe 
developed symptoms 2–5 years after being exposed 
in an endemic country [3] and classical epidemiologi-
cal studies carried out in the 1960s in English sol-
diers returning from India obtained very similar results 
[35]. For these reasons, screening for cysticercosis in 
asymptomatic individuals could be theoretically useful 
in people at risk for NCC to early detect infected sub-
jects, treat them and prevent the onset of symptoms. 
However, there is no practical evidence in favour of 
screening of asymptomatic people [36]. From the scarce 
information on natural evolution of cysticercosis, most 
infected persons will never develop symptoms [37]. For 
example in an endemic rural area of Peru the preva-
lence of NCC according to computed tomography (CT) 
scan (which was offered to all > 18 year-old villagers) 
was 18.8%, but among individuals with NCC only 17% 
reported a history of epilepsy or headache [37].
In symptomatic patients with NCC, growing evidence 
has cumulated about the efficacy of antiparasitic treat-
ment (combined with corticosteroids) in reducing the 
number of brain cysts and the risk of seizure recurrence 
after treatment [38-44]. However, there is no evidence 
that treating an asymptomatic person harbouring a live 
parasite will reduce the probability for neurological 
symptoms in the future and to what extent.
Recently, a multidisciplinary study group on cysticer-
cosis did not recommend serological screening for 
Table 5
Association between seropositivity for cysticercosis and presence of other helminthic infection or eosinophilia in 
internationally adopted children ≤16 years old, Italy, 2001–2016
Other helminthic infection or 
eosinophilia
Positive EITB for cysticercosis Negative EITB for cysticercosis OR 
 
(CI)
p value
na/Nb % nc/Nd %
Hymenolepis nana on stooli 12/37 32.4 147/1,120 13.1
3.18 
 
(1.56–6.6)
0.0008
Other helminthic infectionsj 1/37 2.7 37/1,120 3.3
0.81 
 
(0.11–6.09)
0.8401
Eosinophiliak 11/26 42.3 278/641 43.3
0.96 
 
(0.43–2.12)
0.9147
Other helminthic infection or 
eosinophilia
Positive ELISA for cysticercosis Negative ELISA for cysticercosis OR 
 
(CI)
p value
ne/Nf % ng/Nh %
Hymenolepis nana on stooli 73/133 54.9 200/1,099 18.2
5.47 
 
(3.76–7.95)
< 0.0001
Other helminthic infectionsj 12/133 9.0 72/1,099 6.5
1.41 
 
(0.75–2.68)
0.2856
Eosinophiliak 74/107 69.2 366/805 45.5
2.69 
 
(1.74–4.15)
< 0.00001
CI: confidence interval; EITB: enzyme-linked immune electro transfer blot; ELISA: enzyme-linked immunosorbent assay; OR: odds ratio.
a Number of individuals with the listed feature found seropositive with EITB.
b Number of individuals found seropositive with EITB and with available information on the listed feature.
c Number of individuals found seronegative with EITB and with the listed feature.
d Number of individuals found seronegative with EITB negative and with available information on the listed feature.
e Number of individuals found seropositive with ELISA and with the listed feature.
f Number of individuals found seropositive with ELISA and with available information on the listed feature.
g Number of individuals found seronegative with ELISA and with the listed feature.
h Number of individuals found seronegative with ELISA and with available information on the listed feature.
i Presence of Hymenolepis nana at the parasitological examination of stool.
j Diagnosis of any other helminthic infection through parasitological stool test.
k Eosinophils count > 450 per µL.
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cysticercosis in asymptomatic subjects [45]. Instead, 
the group recommended a careful clinical assessment 
to investigate unrecognised compatible symptoms of 
cysticercosis (a history of convulsions and/or other 
compatible neurological signs or symptoms) and a 
physical examination to detect subcutaneous nodules 
compatible with cysticercosis in persons at high risk 
for cysticercosis. Those considered at high risk were 
patients with confirmed  T. solium  taeniasis, house-
hold and daily contacts of confirmed T. solium  taenia-
sis cases, family members of cysticercosis cases who 
are likely to have been exposed to the same environ-
ment as the index case. The same approach was rec-
ommended for individuals with possible exposure in 
an endemic country before undergoing treatment with 
antiparasitic drugs, such as praziquantel and alben-
dazole, which may cause adverse reactions in case 
of unrecognised cysticercosis. Moreover, individuals 
with compatible signs or symptoms should be fully 
assessed including appropriate brain imaging (CT scan 
and/or MRI) [45]. The utility of a serological screen-
ing for cysticercosis was previously debated by other 
author groups [36], while the US Centers for Disease 
Control and Prevention (CDC) recommends a clinical 
assessment for cysticercosis before prescribing alben-
dazole or praziquantel to refugees in order to avoid 
adverse reactions such as seizures in subjects with 
unrecognised NCC [46].
Our data showed several limitations of serological 
screening for cysticercosis. Firstly, the sensitivity for 
the diagnosis of NCC is low, both for EITB and ELISA 
test (54.5% and 22.2% respectively), with six of 13 chil-
dren with NCC being seronegative. The low sensitivity 
of serological tests can be explained mainly by the 
known low sensitivity (< 50–60%) of serological tests, 
including EITB, in patients with a single brain lesion 
[47] who are the majority of patients in this study 
(n = 7). This was an expected finding, considering that 
a single enhancing lesion is the most common form of 
NCC in children [48].
Moreover, it should be noted that the majority of sub-
jects with NCC (10 of 13) were symptomatic for epilepsy 
and they would be probably diagnosed with NCC even 
without the serological screening. However, three of 
13 children with NCC were asymptomatic and would 
not have been identified in the absence of serological 
screening.
The high rate of individuals with a serological test 
positive for cysticercosis but without a diagnosis of 
NCC may be at least partially explained by possible 
false positivity (cross-reaction) of the test in case 
of infection caused by  H. nana. Intestinal infection 
with H. nana  is a quite frequent finding in IAC and the 
reported prevalence is 1% [49], 2% [50], 9.6% [22], 
according to the different case series. In the present 
study, the prevalence of  H. nana  infection was 17.4%. 
Co-infection with this parasite is therefore common in 
IAC and adds a further limitation to the effectiveness of 
the serological screening for cysticercosis.
Finally, the cost of the screening, EUR 10,372 per case, 
is not negligible, and much higher when compared with 
the reported cost for other infections targeted by dif-
ferent screening protocols, such as latent tuberculosis 
infection [51,52].
Although the epidemiological pattern of IAC in different 
high income countries can change, we think the results 
of our study have a good generalisability. Although 
limited by retrospective nature, this is a wide study, 
with high representation of the different endemic parts 
of the world. However, data concerning the economic 
analysis are based on the current Italian system and 
therefore have a limited external validity.
Another limitation of the study was the inclusion of 
some (n = 27) Eastern European children, screened, 
not systematically, for cysticercosis, despite the pro-
tocol of the ‘National Working Group for the Migrant 
Child’ not recommending the screening of children 
of European origin. The reasons why the clinician in 
charge decided to prescribe the screening are unknown 
Table 6
Costs of services included in the screening algorithm for neurocysticercosis in internationally adopted children ≤16 years 
old, Italy, 2001–2016
Service Number of services used Unitary cost in euros Total cost in euros
ELISA serological testa 1,534 8.8 13,499
EITB serological testb 2,437 36 87,732
Brain MRI without contrastb 175 170 29,750
Infectious diseases’ consultationb 175 22 3,850
The entire screening programme 134,831
EITB: enzyme-linked immune electro transfer blot; ELISA: enzyme-linked immunosorbent assay; MRI: magnetic resonance imaging.
a Cost of the service obtained from ‘Catalogo Regionale 2016’ of the Veneto Region, Italy [33].
b Cost of the service obtained from ‘Catalogo Aziendale 2016’ of the Azienda Ospedaliero-Universitaria Careggi, Florence, Italy [32].
10 www.eurosurveillance.org
(probably eosinophilia). However, we think that the 
inclusion of these children in the analysis has not 
affected the results and our conclusions, since the 
Eastern European children screened were few, only one 
individual was seropositive with ELISA, and no case of 
NCC were diagnosed. Moreover, the choice of using the 
Del Brutto et al. criteria as gold standard for the diag-
nosis of NCC negatively influenced the performance of 
the ELISA test compared with the EITB since only the 
latter is considered among the diagnostic criteria pro-
posed by the authors. However the poor performance 
of ELISA for the diagnosis of NCC has been largely dem-
onstrated [16,53-57].
Finally, the reliability of specificity and NPV of the two 
serological tests is limited since the MRI was not made 
in seronegative subjects.
In conclusion, NCC is rare in IAC and serological 
screening for NCC presents several challenges, such 
as the poor performance of laboratory test, possible 
cross-reaction with other infections, the high cost, the 
unknown benefit of treating subjects with active NCC 
lesions in absence of symptoms. We propose that the 
ongoing serological screening for cysticercosis should 
be discontinued, at least in Italy, unless new evidence 
in support will become available in the future.
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